Multiple myeloma

Multiple myeloma is a type of blood cancer that affects plasma cells, a special type of white blood cell responsible for producing antibodies. In multiple myeloma, these plasma cells become abnormal and multiply uncontrollably, leading to the accumulation of abnormal proteins in the blood. This condition can cause damage to the bones, kidneys, and immune system, resulting in various symptoms and complications.
Treatment options for multiple myeloma typically involve a combination of chemotherapy, immunotherapy, and targeted therapy. Common medications used in the treatment of this condition include:

Bortezomib: A proteasome inhibitor that works by preventing the breakdown of proteins in cancer cells, leading to their death.
Lenalidomide: An immunomodulatory drug that enhances the immune system’s ability to fight cancer cells and promotes apoptosis (cell death) in myeloma cells.
Dexamethasone: A corticosteroid that helps to reduce inflammation and suppress the immune system, making it effective in controlling symptoms and managing the disease.
Daratumumab: A monoclonal antibody that targets the CD38 protein on the surface of myeloma cells, inducing their death and reducing the production of abnormal proteins.
Ixazomib: Another proteasome inhibitor that works similarly to bortezomib in inhibiting protein breakdown and promoting cancer cell death.

Consult with a healthcare professional to determine the most appropriate treatment plan based on individual needs and circumstances. Always follow the prescribed dosage and treatment schedule, and report any side effects or concerns to your healthcare provider.